Home > Journals > Panminerva Medica > Past Issues > Articles online first > Panminerva Medica 2022 Feb 22

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

 

Panminerva Medica 2022 Feb 22

DOI: 10.23736/S0031-0808.22.04641-9

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Metabolic syndrome and bladder cancer

Marialaura RIGHETTO 1 , Daniele MODONUTTI 1, Francesco G. CELSO 1, Vittorio FULCOLI 2, Mariangela MANCINI 1

1 Department of Surgery, Urological Clinic, AULSS 6 Euganea, Camposampiero, Padova, Italy; 2 Department of Surgery, Oncology, and Gastroenterology, Urological Clinic, University of Padova, Padova, Italy


PDF


Metabolic syndrome (MetS) is a widely diffused dysmetabolism, well known to be associated with an increased cardiovascular risk. However, a growing burden of evidence links MetS with several malignancies, potentially influencing the onset, progression, and therapeutic response. In this work, we critically explored the relationship between MetS and bladder cancer through a narrative review, researching the most recent literature on the topic using PubMed, MEDLINE, and EMBASE. We found that the current evidence on the subject is heterogeneous and inconsistent, making it difficult to draw definitive conclusions. Furthermore, since MetS would be a modifiable oncological risk factor, more high-quality data is needed for tailored treatment of bladder cancer.


KEY WORDS: Bladder cancer; Metabolic syndrome; Hypertension; Obesity; Diabetes mellitus

top of page